Prevalence of Hepatitis B Virus Infection in Cameroon: A Systematic Review and Meta-Analysis.

J Viral HepatSep 1, 2026
Clinical ResearchInfectious DiseasesGastroenterologyOpen access

Iya Maliki, Edward J D Webb, Rose Armelle Ada et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed the prevalence of hepatitis B virus (HBV) infection in Cameroon, analyzing 100 studies. The overall prevalence of HBV was found to be 9.98% (95% CI 9.00-11.02), with higher rates in at-risk populations (12.70% vs 8.94% in lower-risk groups).

Key findings

  • Overall HBV prevalence in Cameroon is 9.98% (95% CI 9.00-11.02).
  • Prevalence in higher-risk populations is 12.70% (95% CI 10.28-15.32).
  • Prevalence in lower-risk populations is 8.94% (95% CI 7.84-10.11).
  • High heterogeneity was observed (I 2 = 98.10%).

Why it matters

The high prevalence of HBV in Cameroon highlights a significant public health challenge. Understanding the distribution of HBV can inform targeted interventions and resource allocation to reduce transmission and improve health outcomes.

Source

PubMed · PMID 42554292Free full text on PubMed Central

Published in J Viral Hepat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.